Described herein is a dry powder inhaler which includes: a reservoir containing a dry powder formulation and an arrangement for delivering a metered dose of the medicament from the reservoir; a cyclone deagglomerator for breaking up agglomerates of the dry powder medicament; a delivery passageway for directing an inhalation-induced air flow through a mouthpiece, the delivery passageway extending to the metered dose of medicament, and an inhalable β2-agonist having a particle size distribution of d10<1 μm, d50=1-3 μm, d90=3.5-6 μm and NLT 99% 10 μm and a lactose carrier.

An inhalation device including a housing, which encloses a liquid reservoir in which the liquid is stored before discharge, and an applicator head with a nebulization chamber and an applicator piece connected thereto, wherein the applicator piece is designed either as a mouthpiece, to be received in the mouth of a patient, or as an inhalation mask, to sealingly cover the mouth, the nose, or the mouth and the nose. The inhalation device furthermore has a discharge channel which connects the liquid reservoir to the applicator head. The inhalation device includes at the end of the discharge channel a nozzle plate with a large number of nozzle openings which serve to generate an inhalation mist and through which the liquid from the liquid reservoir is conveyed into the nebulization chamber.

A respiratory care system includes a user interface. A flow indicator is moveable in response to inhalation and/or exhalation, or both, by a user through the user interface. An electronic indicator is operable in response to an electronic signal transmitted in response to the movement of the flow indicator. Methods of use and assembly are also provided.

A stand-alone chamber or multi-chamber inhalation system has at least two alternative vaporized test liquid supply systems for passive or self-administered delivery of vaporized test fluid and air to one or more test chambers, which can be passive or restraint chambers, based on operator selection of delivery on and off times in a passive mode or actuation of an actuator in the chamber by a test animal in a self-administered mode. In one case, a multiple inhalation chamber system has two or more separate test fluid delivery systems and provides options for selective passive uniform drug delivery to multiple chambers or selective delivery of two or more different drugs to different groups of chambers from different delivery systems so that two different drugs or different concentrations of delivered drugs can be tested simultaneously.

The introduction of electronics into a drug delivery device may introduce certain technical challenges, such as durability, electro-mechanical integration, and drug delivery performance. The present disclosure provides solutions for inclusion of an electronics module with an inhaler. For example, heat stakes may be used to secure a printed circuit board (PCB) to an electronics module's housing. Also for example, a slider may be used to transfer vertical movement of an inhaler's yoke to an electronics module's switch. Also for example, certain seals may be used when interfacing the electronics module to other portions of the device's housing to achieve a desired performance.

A system (1) is configured to deliver a liquid substance in the form of dry steam in the context of respiratory therapy. The system (1) comprises:—a reservoir (2) for containing the substance;—dispensing means (6) of the substance in fluid connection with said reservoir (2);—first vibration type electromechanical vaporization means (3), configured to apply vibrations to the substance contained within said reservoir (2) in such a way as to bring the substance into a dry steam state;—second heating vaporization means (4), configured to release thermal energy to the substance contained in said reservoir (2), in such a way as to bring the substance into a dry steam state;—a control unit (7) configured to control the actuation of said first mechanical vaporization means (3) and/or said second heating vaporization means (4) according to a predetermined delivery program.

The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and —a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 15 4.0 μm as measured with a 0.9% (w/v) aqueous solution of sodium chloride; b) a chamber (105) for temporarily accommodating the aerosol generated by the aerosol generator (101), the chamber having an inner lumen with a volume in the range of from about 50 to about 150 ml; and c) a mouthpiece (40) for delivering the aerosol supplied by the nebulizer (100) to the subject, the mouthpiece having an exhalation filter (30).

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.

A ventilator circuit apparatus is provided for the administration of an aerosolized drug from a nebulizer through an endotracheal tube to a patient on a mechanical ventilator with humidification of the breathing gases. Means to disconnect the nebulizer without interrupting the airflow to the patient is provided, with a T-fitting and three-way valve in the ventilator circuit that permits the nebulizer to be bypassed by the airflow, allowing the nebulizer to be removed from the apparatus without interrupting the flow of breathing gases to the patient. In embodiment, the nebulizer is breath-enhanced jet nebulizer. In an embodiment, the jet nebulizer is breath-actuated, by the use of an air pressure sensor that toggles the flow of pressurized air to the nebulizer that drives the jet required for nebulization.

A collapsible inhaler for use with a metered dose inhaler (MDI) dispenser that is operable to dispense a metered dose of medicament therefrom, the inhaler including: an inlet member being adapted to receive an MDI dispenser and having an inlet therein; an outlet member having an outlet therein, a conduit which is pliable and has a distal end associated with the inlet member and a proximal end associated with the outlet member, a support associated with the pliable conduit that is adjustable between an expanded state and a contracted state whereby in the contracted state the inlet member is positioned proximate the outlet member, while in the expanded state the support supports the pliable conduit and combined with the inlet member being spaced from the outlet member that defines a chamber, so that in use a metered dose of medicament can be dispensed from the MDI dispenser through the inlet in the inlet member to mix with air in the chamber and be inhaled by a patient through the outlet in the outlet member, wherein the inhaler further includes a lockout mechanism for inhibiting operation of the MDI dispenser when the support and conduit are in the contracted state and not inhibiting operation of the MDI dispenser when the support and conduit are in the expanded state.